Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era

Whether the LMR at relapse can predict clinical outcomes for relapsed/refractory DLBCL in the rituximab era was investigated. We analyzed 74 patients with relapsed/refractory DLBCL initially treated with a rituximab-containing regimen. A low LMR ( ≤2.6) was significantly associated with shortened OS and PFS. The LMR may facilitate better stratification among patients in the low- and intermediate-risk sIPI groups.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Daisuke Katoh, Yotaro Ochi, Tomohiro Yabushita, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Shuichiro Kaji, Yukihiro Imai, Takayuki Ishikawa Source Type: research